Suzanne L. Topalian
Suzanne Topalian led the first nivolumab trials showing PD-1 blockade works across several cancers.
First author of the 2012 NEJM nivolumab study establishing activity in melanoma, lung and kidney cancer, and pioneer of neoadjuvant immunotherapy as a scientific platform.
| Title | Journal | Year |
|---|---|---|
| Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | New England Journal of Medicine | 2012 |
Pages like this
not linked directly; found by shared links- PersonJulie R. Brahmer
Shares Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer, Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, Nivolumab, PD-1.
- PersonDrew M. Pardoll
Shares Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer, Society for Immunotherapy of Cancer, Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, PD-1.
- PersonF. Stephen Hodi
Shares Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer, Society for Immunotherapy of Cancer, Nivolumab, PD-1.
- IdeaRandomised trials of stopping immunotherapy after one year versus continuing
Shares Nivolumab, PD-1, Melanoma, Immune checkpoint inhibitors.
- PersonTasuku Honjo
Shares Nivolumab, PD-1, Melanoma, Immune checkpoint inhibitors.
- IdeaExtended-interval immunotherapy: give checkpoint inhibitors every 8-12 weeks once stable
Shares Nivolumab, PD-1, Melanoma, Immune checkpoint inhibitors.
- PersonPatrick M. Forde
Shares Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, Nivolumab, PD-1, Non-small-cell lung cancer.
- InstitutionLaura and Isaac Perlmutter Cancer Center at NYU Langone Health
Shares Nivolumab, PD-1, Melanoma, Non-small-cell lung cancer.